Thorotrast induced hepatic cholangiocarcinoma and angiosarcoma

Area of Science:

• Hepatology
• Oncology
• Radiology

Background:

• Thorotrast (thorium dioxide) is a radioactive contrast agent historically used for diagnostic imaging.
• Long-term exposure to Thorotrast is a known risk factor for developing hepatic neoplasms due to its radioactivity.
• The latency period for Thorotrast-induced cancers can be decades.

Observation:

• A 49-year-old woman presented with a diagnosis of liver cancer.
• The patient had a history of Thorotrast administration 22 years prior to diagnosis.
• Imaging and pathological examination revealed two distinct primary liver malignancies: cholangiocarcinoma and angiosarcoma.

Findings:

• This is the first reported case of simultaneous cholangiocarcinoma and angiosarcoma in a patient with a history of Thorotrast exposure.
• The findings highlight the potential for Thorotrast to induce multiple, distinct types of hepatic malignancies.
• The long latency period underscores the chronic risks associated with radioactive contrast agents.

Implications:

• This case expands the known spectrum of Thorotrast-associated hepatic malignancies.
• It emphasizes the importance of long-term patient follow-up for individuals exposed to radioactive contrast agents.
• Further research may be needed to understand the specific mechanisms by which Thorotrast induces different types of liver cancer.